R. Magar

A pharmacoeconomic evaluation of intravenous fosphenytoin (Cerebyx) versus intravenous phenytoin (Dilantin) in hospital emergency departments.

A. Marchetti, E. Sloan, J. Fischer, 1996, Clinical therapeutics.

Duration of effect of botulinum toxin type A in adult patients with cervical dystonia: a retrospective chart review.

A. Marchetti, A. Brashear, M. W. Watts, 2000, Clinical therapeutics.

Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: potential for savings.

A. Marchetti, G. Devercelli, R. Magar, 1999, Clinical therapeutics.

Management of patients with Bacilli Calmette-Guérin-refractory carcinoma in situ of the urinary bladder: cost implications of a clinical trial for valrubicin.

A. Marchetti, P. Schellhammer, D. Lamm, 2000, Clinical therapeutics.

Pharmacotherapies for attention-deficit/hyperactivity disorder: expected-cost analysis.

T. Einarson, A. Marchetti, P. Jensen, 2001, Clinical therapeutics.

Recurrent DKA results in high societal costs – a retrospective study identifying social predictors of recurrence for potential future intervention

L. Fish, R. Magar, Brianna E Johnson-Rabbett, 2021, Clinical Diabetes and Endocrinology.

Clinical and economic impact of new trends in glaucoma treatment.

A. Marchetti, M. Nichol, R. Magar, 2001, MedGenMed : Medscape general medicine.